ALR - Alere Inc.

NYSE - NYSE Delayed Price. Currency in USD
50.99
-50.99 (-100.00%)
Stock chart is not supported by your current browser
Previous Close50.99
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Moody's11 days ago

    Alere Inc. -- Moody's to withdraw Alere's ratings following debt redemption

    Rating Action: Moody's to withdraw Alere's ratings following debt redemption. Global Credit Research- 05 Oct 2017. New York, October 05, 2017-- Moody's Investors Service will withdraw Alere Inc.' s ratings ...

  • PR Newswire13 days ago

    Lifshitz & Miller LLP Announces Investigation of Alere Inc., Emergent BioSolutions, Inc., Frontier Communications Corporation, HSN, Inc., Insys Therapeutics Inc., LSB Industries, Inc. and Otonomy, Inc.

    NEW YORK , Oct. 3, 2017 /PRNewswire/ -- Alere Inc. (ALR) Lifshitz & Miller announces that on August 23, 2017 , the U.S. District Court for the District of Massachusetts denied ALR's motion to dismiss a ...

  • Abbott to Gain from Alere's Takeover Due for Oct 3 Closure
    Zacks14 days ago

    Abbott to Gain from Alere's Takeover Due for Oct 3 Closure

    Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.

  • Market Realist14 days ago

    Abbott-Alere Deal Wins Conditional US Antitrust Approval

    The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories' (ABT) acquisition of Alere (ALR).

  • See what the IHS Markit Score report has to say about Alere Inc.
    Markit15 days ago

    See what the IHS Markit Score report has to say about Alere Inc.

    Short interest is low for ALR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding ALR are favorable, with net inflows of $2.40 billion.

  • ACCESSWIRE15 days ago

    Corporate News Blog - Alere Announces Agreement with the US Department of Justice; Settles the Investigations Concerning Previous Foreign Acquisitions

    LONDON, UK / ACCESSWIRE / October 2, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Alere Inc. (NYSE: ALR ), following which we have published a free ...

  • PR Newswire15 days ago

    Alere Receives FDA Clearance for Alere™ i Influenza A & B 2 Rapid Molecular Test

    WALTHAM, Mass., Oct. 2, 2017 /PRNewswire/ -- Alere Inc. (ALR), a global leader in rapid diagnostics, today announced that its Alere™ i Influenza A & B 2 test has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for the detection of influenza A and B infection in children and adults. Alere i Influenza A & B 2 is a second-generation rapid molecular assay, which delivers lab accurate results in less time, with the ability to report a positive result in as little as 5 minutes. Alere i Influenza A & B 2 also offers increased sample flexibility with nasopharyngeal swabs now validated for direct use, as well as, in transport media.

  • GuruFocus.com18 days ago

    Alere Reaches Settlement With SEC

    The company will pay $13 million

  • PR Newswire18 days ago

    Alere Announces the U.S. Department of Justice Closes Investigation

    WALTHAM, Mass. , Sept. 29, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced the U.S. Department of Justice (the "DOJ") ...

  • Abbott Labs' Torturous Deal Saga Isn't Over Yet
    Bloomberg18 days ago

    Abbott Labs' Torturous Deal Saga Isn't Over Yet

    The takeover is set to close next week, but the medical-device maker still has to prove it was all worth it.

  • PR Newswire18 days ago

    Abbott Acquisition of Alere Set to Close on October 3, 2017

    WALTHAM, Mass., Sept. 29, 2017 /PRNewswire/ -- Alere Inc. (ALR) announced today that Abbott's acquisition of Alere is intended to close on October 3, 2017. Alere intends to request that the New York Stock Exchange cease trading of Alere's common stock before market open on October 3, 2017. Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™.

  • PR Newswire18 days ago

    Alere Announces Agreement in Principle to Settle with the U.S. Department of Justice

    WALTHAM, Mass., Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that it has reached an agreement in principle to settle with the U.S. Department of Justice (the "DOJ") to resolve various potential civil claims, including claims under the False Claims Act, relating to Alere Triage® cardiac and Toxicology products sold between January 2006 and March 31, 2012. The settlement relates to matters arising out of the previously disclosed 2012 FDA inspection of Alere San Diego and the Office of Inspector General subpoena.

  • The Wall Street Journal18 days ago

    [$$] Alere Settles With SEC Over Accounting-Fraud Allegations

    Alere Inc. has agreed to pay $13 million to settle allegations from the Securities and Exchange Commission that its foreign subsidiaries committed accounting fraud and used third parties to make improper ...

  • TheStreet.com19 days ago

    FTC Approves Abbott's Acquisition of Alere, Stock Jumps

    Abbott was able to reach a deal to buy Alere in April for around $5.3 billion, below its initial $5.8 billion offer.

  • Abbott wins U.S. antitrust approval to buy Alere with conditions
    Reuters19 days ago

    Abbott wins U.S. antitrust approval to buy Alere with conditions

    Abbott Laboratories has won U.S. antitrust approval to buy Alere Inc on condition that it sell two point-of-care medical testing businesses, the Federal Trade Commission said on Thursday. Alere's shares were up 3.5 percent at $50.61 in mid-afternoon trading on Thursday while Abbott was up 3 percent at $53.72. Abbott first offered to buy Alere in February 2016, but the deal ran into trouble because of issues related to the diagnostic maker's accounting and sales practices.

  • Reuters19 days ago

    Alere to pay more than $13 million to resolve U.S. SEC probe

    Alere Inc has agreed to pay more than $13 million to resolve charges the diagnostic testing firm committed accounting fraud and made improper payments to foreign officials, the U.S. Securities and Exchange Commission said on Thursday. The settlement with Alere resolved an investigation that began in 2015 before Abbott Laboratories agreed to buy the Waltham, Massachusetts-based company in a $5.3 billion deal expected to close later this year.

  • PR Newswire19 days ago

    Alere Announces Settlement with SEC

    WALTHAM, Mass. , Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that it has reached a settlement with the United ...

  • Alere, Inc. – Value Analysis (NYSE:ALR) : September 21, 2017
    Capital Cube26 days ago

    Alere, Inc. – Value Analysis (NYSE:ALR) : September 21, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Alere, Inc. a score of 6. Our analysis is based on comparing Alere, Inc. with the following peers – Quidel Corporation, Bio-Rad Laboratories, Inc. Class A, Abbott Laboratories, Chembio Diagnostics, Inc., Danaher Corporation, Procter & Gamble Company, Hill-Rom Holdings, Inc., OraSure Technologies, Inc., Meridian Bioscience, Inc. and ... Read more (Read more...)

  • Here's Why Quidel Corporation Stock Is Popping Today
    Motley Fool28 days ago

    Here's Why Quidel Corporation Stock Is Popping Today

    Investors appear pleased with a recent revision to a deal with another point-of-care diagnostic developer.

  • Alere, Inc. breached its 50 day moving average in a Bullish Manner : ALR-US : September 19, 2017
    Capital Cube28 days ago

    Alere, Inc. breached its 50 day moving average in a Bullish Manner : ALR-US : September 19, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alere, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)

  • PR Newswire28 days ago

    Alere Announces Intent to Voluntarily Delist Series B Convertible Perpetual Preferred Stock from the NYSE Conditioned Upon the Completion of its Acquisition by Abbott

    WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ -- Alere Inc. (ALR) ("Alere"), today announced that it has submitted written notice to the New York Stock Exchange (the "NYSE") of its intention to voluntarily delist its Series B Convertible Perpetual Preferred Stock, par value $0.001 per share (the "Preferred Stock"), from the NYSE. The voluntary delisting is subject to and conditioned upon the completion of its acquisition by Abbott Laboratories, an Illinois corporation ("Abbott"). Abbott has informed Alere that it intends to consummate its offer to purchase all outstanding shares of the Preferred Stock (the "Offer") following the completion of the acquisition of Alere and upon satisfaction of all other conditions to the Offer, and thereafter to cancel all remaining shares of Preferred Stock in exchange for the liquidation preference, plus accrued but unpaid dividends, due on such shares of Preferred Stock.

  • PR Newswire28 days ago

    Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock

    WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ -- Alere Inc. (ALR), a global leader in rapid diagnostics, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE:ALR-B). Such payment will cover the amount of all dividends accrued from July 1, 2017 through September 30, 2017. Abbott Laboratories has made an offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock at $402.00 per share, plus accrued but unpaid dividends to, but not including, the settlement date of the offer.  For more details, see the Tender Offer Statement on Schedule TO (together with the exhibits and amendments thereto) filed by Abbott with the Securities and Exchange Commission on July 17, 2017.

  • Business Wirelast month

    ALERE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alere Inc. - ALR

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Alere Inc.

  • See what the IHS Markit Score report has to say about Alere Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Alere Inc.

    Short interest is low for ALR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold ALR had net inflows of $945 million over the last one-month.